What Penny Stocks to Buy Today? 7 Small-Caps to Watch Right Now
Which penny stocks are on your watchlist today? Here’s 7 for some inspiration
The post What Penny Stocks to Buy Today? 7 Small-Caps to Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Are These Penny Stocks Worth Watching in June 2021?
Looking for the best penny stocks to buy in 2021? There are a few things to consider when making a watchlist right now. In late June, one of the bigger impacting factors aside from Covid-19 is cryptocurrency. Yesterday on June 22nd, we witnessed both Bitcoin price and Dogecoin price drop substantially during the trading day. At one point, Bitcoin dipped below $30,000, while albeit climbing back up only a few hours later. And today on June 23rd, the complete opposite is occurring.
As of mid-morning, DOGE is up by around 13% and BTC is sitting comfortably at around $34,000 per coin. While this is not a full rebound to its previous highs, it is a great sign for bullish crypto and penny stocks investors. And while cryptocurrency and penny stocks are very different assets, they can at times trade in tandem with one another.
Additionally, today the Supreme Court ruled against the private shareholders of Freddie Mae and Fannie Mac (FNMA stock and FMCC stock), who argued to allow for the privatization of the business. This comes after a years long battle following the mortgage crisis when the Federal Government took over ownership of the agencies to avoid a further housing market crash.
In return for a major $100 billion investment into FNMA and FMCC stock, the companies would pay all profits to the Feds for the foreseeable future. And today, the Supreme Court upheld that ruling, resulting in a solid bearish drop for both these companies. So, with all of this in mind, let’s take a look at seven must-watch penny stocks right now.
BEST Inc. is a penny stock we’ve been covering for quite some time now. For some context, it is a smart supply chain solutions company and logistics provider based in China. It operates proprietary technology and extensive networks to deliver both logistics and value-added services. Today, shares of BEST stock pushed up by a staggering 28% at midday, indicating solid bullish sentiment.
In China, inter-country commerce is a major industry. For that reason, the need for trucking services is always extremely high. BEST offers last-mile services, truckload brokerage, and much more, which place it as one of the most prominent logistics companies in the Chinese delivery market.
In its unaudited financial results for the first quarter of 2021, the company managed to increase its revenue YoY by more than 29% to $991 million. While it did pull in a net loss of $92 million, its EBITDA managed to remain relatively stable. This report is a reflection of both the pandemic and the end of the pandemic, which means that the negative could be taken with a grain of salt. Considering this, will it be on your watchlist?
Farmmi Inc. (NASDAQ: FAMI)
Today, exciting news dropped for FAMI as it announced a strategic investment and cooperation agreement. Before we get into it, let’s talk about what Farmmi does. Farmmi is a provider of agricultural products such as Shiitake mushrooms, Mu Er mushrooms, edible fungi, and much more. This allows it to be a major supplier of these products in China, which are in very high demand. Additionally, it exports its fungi products internationally, which has become a major market in the past few years.
Today, the company announced a strategic investment and cooperation agreement with its subsidiary Farmmi Enterprise Management Co. Ltd. and Sigma Holding Co. Ltd./Hangzhou Xuyue Interactive Culture and Media Co. Ltd. This will allow for a major expansion of its distribution network. The companies will together build a new company which will be part of a 50-year agreement to provide community group purchasing options for Farmmi’s products.
“We are partnering with two strong companies, which will give the new company the financial resources and expertise critical to a successful launch. We have conducted extensive market research and have a plan in place to ensure we move quickly and begin capturing our share of the large distribution opportunity.”
CEO of Farmmi Inc., Ms. Yefang Zhang
With this big news in mind, will FAMI stock be on your watchlist moving forward?
Enzolytics Inc. (OTC: ENZC)
Up by a solid 7%, or so at midday are shares of ENZC stock. Enzolytics is a biotech penny stock that is developing and commercializing therapeutics for the treatment of infectious diseases. This includes ITV-1, a treatment for HIV/AIDS, and more. Only a few weeks ago, it announced definitive plans to advance its ITV-1 anti-HIV therapeutic in clinical trials throughout Europe. This will hopefully bring in a new and major revenue stream for the company as well as help the patients suffering from this terrible ailment worldwide.
It recently formed International Medical Partners Ltd. in partnership with several major European companies. This will help the distribution of ITV-1 in more than 27 countries across Europe. And it recently engaged Contract Research Organization Clinical Design Ltd. to establish a new drug program for human clinical trials regarding ITV-1. This is all big news and shows that ENZC is making sizable progress in the biotech industry. Whether it’s enough to consider ENZC for your list of penny stocks to watch, is up to you.
Ashford Hospitality Trust (NYSE: AHT)
AHT is another penny stock that we have discussed frequently in the past few months. After making a sizable dip yesterday, shares of AHT are correcting upward today. Ashford Hospitality is a REIT focused on the upscale hospitality market. Its investments include hotels, resorts, and more. The reason for the sizable drop yesterday came as a regulatory filing showed that a company called Seven Knots had purchased around 40 million new shares of AHT. The entity will sell shares ‘from time to time’, and its total purchase price comes out to roughly $217 million in proceeds for AHT.
While this seems like a positive announcement, the issue comes with share dilution. Of its total outstanding 200 million shares before this, 40 million more is a sizable number. This means that those 200 million shares may have just become around 20% more diluted. While this is not a huge deal in the short term, investors are waiting to see the longer-term implications of this share purchase. Considering this, is AHT worth watching or not?
Ideanomics Inc. (NASDAQ: IDEX)
Up by a solid 6%, or so at midday is IDEX stock. While big news dropped today, it’s worth understanding what IDEX does before we get into it. Ideanomics works in two main divisions; Ideanomics Mobility and Ideanomics Capital. The first is its investment into the electric car and vehicle industry, and the second contains its investments in the growing fintech market. While IDEX has a lot to offer on its own, it is also widely regarded as a meme stock that is highly popular on Reddit and Twitter.
Very recently, it announced the purchase of Soletrac, an electric tractor company based in Santa-Rosa California, for around $20 million. Last year, it provided a $1.3 million investment into the company, which we see has evolved into a complete purchase of the company. This aligns with its strategy of working to boost the EV infrastructure market.
While the electric automobile market is relatively saturated, there is a massive unmet need in agriculture. Agriculture amounts to an incredibly high demand for fossil fuels, and fuel is one of the main costs associated with producing food. For this reason, Ideanomics sees a massive opportunity here to get in early. This is big news and should be taken into consideration when looking at IDEX stock.
Vinco Ventures Inc. (NASDAQ: BBIG)
Vinco Ventures is another meme penny stock that is highly discussed across social media. While shares are down slightly today, in the past month, BBIG stock has shot up by over 35% and in the past six months by over 250%. This is a staggering gain and is reflective of both its status as a trending penny stock and its business model. Aside from the acquisition of Lomotif which we’ve discussed frequently in the past few weeks, Vinco Ventures works in the digital media and entertainment industry.
It provides investments for companies looking to grow in this market, and utilities its Buy. Innovate. Grow. Or B.I.G. strategy. After investing in these companies, it works to both scale and improve the underlying business models. Given that the demand for digital entertainment has increased substantially during the pandemic, many investors are focused on BBIG stock. With the recent aforementioned acquisition, it’s no wonder that so many traders consider it a penny stock to watch.
Acasti Pharma Inc. (NASDAQ: ACST)
Acasti Pharma Inc. is another trending penny stock and one that has posted substantial gains in the past few months. Up by around 10% today, shares have pushed up by around 45% since mid-April of this year. While ACST stock did push up by around 35% in pre-market, shares quickly corrected as soon as trading commenced. This rise follows the company’s recent plans to acquire Grace Therapeutics as well as its fast-paced development of the compound CaPre.
The company states that this acquisition will provide both revenue and a new method of drug delivery technology for treating both rare and orphan diseases. And, Grace’s most developed compound already has a clear and concise track to gaining approval from the FDA. With an approved drug, Grace could be well on the way to the commercialization phase, which is always the best aspect for investors to hear. Considering this, will ACST stock be on your list of penny stocks to watch?
Why Penny Stocks Are so Popular Right Now
Penny stocks remain some of the most popular securities for investors to buy right now. This is due to their low price and the large intraday moves we see throughout the list of penny stocks. While prices move fast and volatility is often extremely high, the opportunities here are almost unparalleled.
Considering this, there are hundreds of penny stocks showing potential right now. Utilizing research and information will help to separate the winners from the losers. With all of this in mind, it’s no wonder that penny stocks are so popular right now.
Pharma industry reputation remains steady at a ‘new normal’ after Covid, Harris Poll finds
The pharma industry is hanging on to reputation gains notched during the Covid-19 pandemic. Positive perception of the pharma industry is steady at 45%…
The pharma industry is hanging on to reputation gains notched during the Covid-19 pandemic. Positive perception of the pharma industry is steady at 45% of US respondents in 2023, according to the latest Harris Poll data. That’s exactly the same as the previous year.
Pharma’s highest point was in February 2021 — as Covid vaccines began to roll out — with a 62% positive US perception, and helping the industry land at an average 55% positive sentiment at the end of the year in Harris’ 2021 annual assessment of industries. The pharma industry’s reputation hit its most recent low at 32% in 2019, but it had hovered around 30% for more than a decade prior.
Rob Jekielek
“Pharma has sustained a lot of the gains, now basically one and half times higher than pre-Covid,” said Harris Poll managing director Rob Jekielek. “There is a question mark around how sustained it will be, but right now it feels like a new normal.”
The Harris survey spans 11 global markets and covers 13 industries. Pharma perception is even better abroad, with an average 58% of respondents notching favorable sentiments in 2023, just a slight slip from 60% in each of the two previous years.
Pharma’s solid global reputation puts it in the middle of the pack among international industries, ranking higher than government at 37% positive, insurance at 48%, financial services at 51% and health insurance at 52%. Pharma ranks just behind automotive (62%), manufacturing (63%) and consumer products (63%), although it lags behind leading industries like tech at 75% positive in the first spot, followed by grocery at 67%.
The bright spotlight on the pharma industry during Covid vaccine and drug development boosted its reputation, but Jekielek said there’s maybe an argument to be made that pharma is continuing to develop innovative drugs outside that spotlight.
“When you look at pharma reputation during Covid, you have clear sense of a very dynamic industry working very quickly and getting therapies and products to market. If you’re looking at things happening now, you could argue that pharma still probably doesn’t get enough credit for its advances, for example, in oncology treatments,” he said.
The COVID pandemic transformed our lives in ways many of us are still experiencing, four years later. One of these changes was the significant uptake in gaming as a hobby, chief among them being “cosy games” like Animal Crossing: New Horizons (2020).
Players sought comfort in these wholesome virtual worlds, many of which allowed them to socialise from the safety of their homes. Cosy games, with their comforting atmospheres, absence of winning or losing, simple gameplay, and often heartwarming storylines provided a perfect entry point for a new hobby. They also offered predictability and certainty at a time when there wasn’t much to go around.
Cosy games are often made by small, independent developers. “Indie games” have long been evangelised as the purest form of game development – something anyone can do, given enough perseverance. This means they can provide an entry point for creators who hadn’t made games before, but were nevertheless interested in it, enabling a new array of diverse voices and stories to be heard.
In May 2020, near the start of the pandemic, the small poetry game A Solitary Spacecraft, which was about its developer’s experience of their first few months in lockdown, was lauded as particularly poignant. Such games showcase a potential angle for effective cosy game development: a personal one.
Personal themes are often explored through cosy games. For instance, Chicory and Venba (both released in 2023) tackle difficult topics like depression and immigration, despite their gorgeous aesthetics. This showcases the diversity of experiences on display within the medium.
Historically, restructurings like these, or discontent with working conditions, have led talented laid-off developers to create their own companies and explore indie development. In the wake of the pandemic and the cosy game boom, these developers may have more personal stories to tell.
Making my own cosy game
I developed my own cosy and personal game during the pandemic and quickly discovered that creating these games in a post-lockdown landscape is no mean feat.
What We Take With Us (2023) merges reality and gameplay across various digital formats: a website, a Discord server that housed an online alternate reality game and a physical escape room. I created the game during the pandemic as a way to reflect on my journey through it, told through the videos of game character Ana Kirlitz.
The trailer for my game, What We Take With Us.
Players would follow in Ana’s footsteps by completing a series of ten tasks in their real-world space, all centred on improving wellbeing – something I and many others desperately needed during the pandemic.
But creating What We Take With Us was far from straightforward. There were pandemic hurdles like creating a physical space for an escape room amid social distancing guidelines. And, of course, the emotional difficulties of wrestling with my pandemic journey through the game’s narrative.
These struggles were starkly contrasted by the feedback I received from players who played the game, however.
This is a crucial lesson for indie developers: the creator’s journey and the player’s experience are often worlds apart. Cosy, personal games, as I discovered, can change the lives of those who play them, no matter how few they reach. They can fundamentally change the way we think about games, allow us to reconnect with old friends, or even inspire us to change careers – all real player stories.
Lessons in cosy game development
I learned so much about how cosy game development can be made more sustainable for creators navigating the precarious post-lockdown landscape. This is my advice for other creators.
First, collaboration is key. Even though many cosy or personal games (like Stardew Valley) are made by solo creators, having a team can help share the often emotional load. Making games can be taxing, so practising self-care and establishing team-wide support protocols is crucial. Share your successes and failures with other developers and players. Fostering a supportive community is key to success in the indie game landscape.
Second, remember that your game, however personal, is a product – not a reflection of you or your team. Making this distinction will help you manage expectations and cope with feedback.
Third, while deeply considering your audience may seem antithetical to personal projects, your game will ultimately be played by others. Understanding them will help you make better games.
The pandemic reignited the interest in cosy games, but subsequent industry-wide troubles may change games, and the way we make them, forever. Understanding how we make game creation more sustainable in a post-lockdown, post-layoff world is critical for developers and players alike.
For developers, it’s a reminder that their stories, no matter how harrowing, can still meaningfully connect with people. For players, it’s an invitation to embrace the potential for games to tell such stories, fostering empathy and understanding in a world that greatly needs it.
Looking for something good? Cut through the noise with a carefully curated selection of the latest releases, live events and exhibitions, straight to your inbox every fortnight, on Fridays. Sign up here.
Adam Jerrett does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
The SNF Institute for Global Infectious Disease Research announces new advisory board
From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in…
From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in the 1970s, combating infectious disease has a rich history at Rockefeller. That tradition continues as the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller University (SNFiRU) caps a successful first year with the establishment of a new advisory board.
Credit: Lori Chertoff/The Rockefeller University
From identifying the influenza virus that caused the pandemic of 1918 to developing vaccines against pneumococcal pneumonia and bacterial meningitis in the 1970s, combating infectious disease has a rich history at Rockefeller. That tradition continues as the Stavros Niarchos Foundation Institute for Global Infectious Disease Research at Rockefeller University (SNFiRU) caps a successful first year with the establishment of a new advisory board.
This international advisory board was created in part to give guidance on how to best use SNFiRU’s resources, as well as bring forward innovative ideas concerning new avenues of research, public education, community engagement, and partnership projects.
SNFiRU was established to strengthen readiness for and response to future health crises, building on the scientific advances and international collaborations forged in the context of the COVID-19 pandemic. Launched with a $75 million grant from the Stavros Niarchos Foundation (SNF) as part of its Global Health Initiative (GHI), the institute provides a framework for international scientific collaboration to foster research innovations and turn them into practical health benefits.
SNFiRU’s mission is to better understand the agents that cause infectious disease and to lower barriers to treatment and prevention globally. To speed this work, the institute launched numerous initiatives in its inaugural year. For instance, SNFiRU awarded 31 research projects in 29 different Rockefeller laboratories for over $5 million to help get collaborative new research efforts off the ground. SNFiRU also supports the Rockefeller University Hospital, where clinical studies are conducted, and brought on board its first physician-scientist through Rockefeller’s Clinical Scholars program. “One of the surprises was the scope of interest from Rockefeller scientists in using their talents to tackle important infectious disease problems,” says Charles M. Rice, Maurice R. and Corinne P. Greenberg Professor in Virology at Rockefeller and director of SNFiRU. “The research topics range from the biology of infectious agents to the dynamics of the immune response to pathogens, and also include a number of infectious disease-adjacent studies.”
In the past 12 months, SNFiRU often brought together scientists studying different aspects of infectious disease as a way to spur new collaborations. In addition to hosting its first annual day-long symposium, SNFiRU initiated a Young Scientist Forum for students and post-doctoral fellows to meet regularly, facilitating cross-laboratory thinking. A bimonthly seminar series has also been established on campus.
Another aim of SNFiRU is to develop relationships with community-based organizations, as well as design and participate in community-engaged research, with a focus on low-income and minority communities. To that end, SNFiRU is helping develop a research project on Chagas disease, a tropical parasitic infection prevalent in Latin America that can cause congestive heart failure and gastrointestinal complications if left untreated. The project will bring together clinicians practicing at health centers in New York, Florida, Texas, and California and basic scientists from multiple institutions to help the communities that are most impacted.
“The SNFiRU international advisory board convenes globally recognized leaders with distinguished biomedical expertise, unrivalled experience in pandemic preparedness and response, and a shared commitment to translating scientific advancements into equitably distributed benefits in real-world settings,” says SNF Co-President Andreas Dracopoulos. “The advisory board will advance the institute’s indispensable mission, which SNF is proud to support as a key part of our Global Health Initiative, and we look forward to seeing breakthroughs in the lab drive better outcomes in lives around the globe.”
The new advisory board will hold its first meeting on April 11th, 2024, following the second annual SNF Institute for Global Infectious Disease Research Symposium at Rockefeller.
Its members are: Rafi Ahmed of Emory University School of Medicine, Cori Bargmann of The Rockefeller University, Yasmin Belkaid of the Pasteur Institute, Anthony S. Fauci, the former director of the National Institute of Allergy and Infectious Diseases, Peter Hotez of Baylor College of Medicine and Texas Children’s Hospital Center for Vaccine Development, Esper Kallas of of the Butantan Institute, Sharon Lewin of the University of Melbourne Doherty Institue, Carl Nathan of Weill Cornell Medicine, Rino Rappuoli of Fondazione Biotecnopolo di Siena and University of Siena, and Herbert “Skip” Virgin of Washington University School of Medicine and UT Southwestern Medical Center.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
